GlobalLogic Launches Women Influencers Program to Promote Diverse Leadership Development
11.5.2022 15:00:00 EEST | Business Wire | Press release
GlobalLogic Inc., a Hitachi Group company and leader in Digital Engineering, has launched the Women Influencers Program, designed to encourage and enable women employees interested in exploring cross-functional management positions within the technology firm. As part of the company’s focus on DEI (Diversity, Equity, Inclusion), GlobalLogic is aiming for greater diversity at all levels in the workforce across gender, sexual orientation, color, ethnic origin, age and ability. The Women Influencers Program is specifically focused to promote greater gender diversity especially among the company’s leadership ranks. The Program will provide developmental and mentoring opportunities through GlobalLogic’s People Development function and individual business units.
Core Program Elements
The Program centers around nine competencies that participants will explore via a set of learning modules, with an entire Program journey expected to last five to six months. Operating in tandem, global cohorts of women based across the globe will join together to share and learn from collective experiences.
The competencies promote the development of “soft” skills – meaning those not directly tied to a formal educational program but rather gained through experience and from peers. These competencies include directness and candor, inspiring and influencing others, effective decision making, professional network development, and the continued development of communication skills. Program participants will also receive training specific to GlobalLogic’s capabilities which are meant to enhance essential corporate knowledge and increase depth of technical competencies.
"Diversity, equity, and inclusion are paramount to GlobalLogic's success," said Amy Hanlon-Rodemich, Chief People Officer, GlobalLogic. "We created the Women Influencers Program to elevate emerging women leaders and to prepare them to take on a wider range of roles and responsibilities including expansion into senior leadership roles. This Program will enable more women leaders to take on more strategic positions within the company."
Based on Research
Initially piloted in India in 2020, the Program’s intent was to actively focus on enhancing the company’s management pipeline with a consideration toward diversity and inclusivity; particularly for women within the company. Upon conducting in-depth analysis of leadership roles and paths to those positions, GlobalLogic’s Program development team discovered that while the digital engineering firm’s overall diversity stats were above the industry average, an even more diverse senior management team would be a tremendous enhancement to the current management ranks.
Research suggests that the female-to-male disparity is due to multiple factors, including prioritization of personal and family life, cultural demands and differences, and organizational dynamics. It was also noted that many women express a distinct “burn out” effect, indicating an ongoing struggle to identify resources and opportunities for progressing their careers.
In response, the Program development team explored options for accelerating women’s career paths by developing essential leadership skills and helping them becoming future ready, positioning participants to take on new roles within GlobalLogic.
“Our aim is to correct the imbalance in women holding leadership roles versus men, which is common throughout the technology industry according to global statistics,” said Shivani Khanna, Senior Manager, People Team, GlobalLogic. “We believe that through our Program’s structured guidance and encouragement, we can positively shift that dynamic.”
Establishing a Supportive Ecosystem
The ecosystem being developed by GlobalLogic will include “Anchors,” a role held by members of the human resources team who will help ensure that the Program is operating effectively. Anchors will also manage the learning and mentor groups that will spearhead the specific activities designed to provide the professional skills previously referenced.
Participants’ managers will be enlisted as “Program Catalysts” responsible for ensuring that the Program is not simply a training exercise but rather a complete learning journey championing employee learning and advancement across the organization.
“Program Sponsors — the managers and mentors — will act as coaches overseeing the employees’ journeys. They will help steer participants toward the content and activities appropriate to each individual’s unique path,” Khanna continued. “We’re excited to officially launch this Program in GlobalLogic locations around the world.”
About GlobalLogic
GlobalLogic (www.globallogic.com) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.
GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220511005037/en/
Contact information
GlobalLogic, Inc. (Global)
Heather Ailara
211 Communications
+1.973.567.6040
heather@211comms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
